Skip to main content
NeoImmuneTech, Inc. logo

NeoImmuneTech, Inc. — Investor Relations & Filings

Ticker · 950220 ISIN · KR8840140006 LEI · 254900489QR747TPTT13 KO Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2025-11-07 Interim / Quarterly Rep…
Country US United States of America
Listing KO 950220

About NeoImmuneTech, Inc.

https://www.neoimmunetech.com/en

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2025.09)
Interim / Quarterly Report Classification · 100% confidence The document is titled '분기보고서' which translates to 'Quarterly Report' and specifies the period from January 1, 2025 to September 30, 2025, indicating it covers a fiscal quarter or three quarters. It contains detailed financial and operational information including company overview, capital changes, stock information, business activities, sales, risk management, and major contracts. The length is about 15,000 characters, which is substantial and contains actual financial data and analysis. It is not a brief announcement or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-11-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' which translates to 'Report on Large Shareholding Status'. It details changes in share ownership, including specific share counts, ownership percentages, and changes in major shareholders. It references legal provisions related to capital markets and financial investment laws, and includes detailed tables of shareholdings and changes. This type of document corresponds to notifications about major shareholding changes, typically filed when significant shareholders cross ownership thresholds or change their holdings materially. It is not an annual report, earnings release, or management report, nor is it a proxy or voting result announcement. The content is consistent with a Major Shareholding Notification filing.
2025-10-16 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document text is a formal announcement regarding a change in the company's CEO (대표이사 변경). It includes details such as the previous CEO's name, the reason for change (resignation due to personal reasons), the date of change, board resolution date, attendance of outside directors, and interim CEO appointment. There is no financial data, no mention of financial results, reports, or presentations. The document is short (1079 characters) and purely an announcement of management change. This fits the category of Board/Management Information (MANG).
2025-10-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by insiders or major shareholders to report changes in their shareholdings. This falls under the category of 'Director's Dealing' (DIRS) as it details the acquisition of shares by a major shareholder (Genexine) in the issuing company (NeoImmuneTech).
2025-09-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a mandatory regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (Genexine, Inc.) in NeoImmuneTech, Inc. due to a capital increase (rights offering). This falls under the category of Major Shareholding Notification (MRQ), as it tracks significant changes in ownership levels and voting rights.
2025-09-18 Korean
증권발행결과(자율공시) (주주배정 후 실권주 일반공모)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (capital increase via rights offering followed by a public offering). It details the number of shares issued, the total amount raised, and the payment completion date. This falls under the category of share issuance and capital changes.
2025-09-16 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.